Showing results (451-460 of 1,350) with videos related to
Sort By:
Pageof 135
Clinical Pharmacology in Drug Development|April 28, 2016
Perspectives in Drug Development and Clinical Pharmacology: The Discovery of Histamine H1 and H2 AntagonistsAlan Wayne JonesClinical Pharmacology in Drug Development|April 29, 2016
Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult VolunteersAlienor Berges, Jonathan Robertson, James Upward, et al.Clinical Pharmacology in Drug Development|April 29, 2016
Vancomycin: Predictive Performance of a Population Pharmacokinetic Model and Optimal Dose in Neonates and Young InfantsAmélie Marsot, Renaud Vialet, Audrey Boulamery, et al.Clinical Pharmacology in Drug Development|April 29, 2016
Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy SubjectsEarvin Liang, Pamela Garzone, Jesse M Cedarbaum, et al.Clinical Pharmacology in Drug Development|April 29, 2016
Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal CancerBing-Bing Yang, Chi-Yuan Wu, Eric Chen, et al.Clinical Pharmacology in Drug Development|April 29, 2016
Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 DiabetesRebecca J Hodge, Jiang Lin, Lakshmi S Vasist Johnson, et al.Clinical Pharmacology in Drug Development|April 29, 2016
Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male SubjectsDagmar Kubitza, Michael Becka, Stephan Schwers, et al.Clinical Pharmacology in Drug Development|April 29, 2016
Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis CTimothy Eley, Bing He, Shu-Pang Huang, et al.Clinical Pharmacology in Drug Development|April 29, 2016
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy SubjectsNobuko Matsushima, Frank Lee, Toshiyuki Sato, et al.Clinical Pharmacology in Drug Development|April 29, 2016
Pharmacokinetics of a Single 150-mg Intravenous Infusion of Fosaprepitant: Effects of Concentration and Infusion Time in Healthy Japanese MenJunichi Azuma, Hiroyuki FukasePageof 135